Telephone: 608-263-3035; FAX: 608-263-3104
Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension†
Article first published online: 29 MAY 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 18, Issue 6, pages 686–695, June 2012
How to Cite
Hollatz, T. J., Musat, A., Westphal, S., Decker, C., D'Alessandro, A. M., Keevil, J., Zhanhai, L. and Runo, J. R. (2012), Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl, 18: 686–695. doi: 10.1002/lt.23407
Potential Conflicts of Interest: James R. Runo has served as a consultant/and or speaker for Actelion, Gilead, United Therapeutics, and Pfizer; his last activity with any company occurred in 2008, and there has been none since. He is also an investigator in a United Therapeutics–sponsored trial (Open-Label Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension; ClinicalTrials.gov identifier NCT01028651), but he has not enrolled any patients. In addition, he has served as a local investigator for multicenter studies with Actelion.
- Issue published online: 29 MAY 2012
- Article first published online: 29 MAY 2012
- Accepted manuscript online: 8 FEB 2012 12:47AM EST
- Manuscript Accepted: 2 FEB 2012
- Manuscript Received: 23 SEP 2011
- 20Portopulmonary hypertension: a report from the US-based REVEAL registry. Chest; doi:10.1378/chest.11-0160., , , , , , .